{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:13:44Z","timestamp":1763018024983},"reference-count":104,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec><jats:title>Purpose of review<\/jats:title><jats:p>Uncertainty persists about the contribution of lipids to the increased risk of cardiovascular disease (CVD) among rheumatoid arthritis and other inflammatory joint disease (IJD) patients. In reviewing recent research, we consider potential insights gained by quantifying lipoprotein particles directly, rather than by their lipid content.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent findings<\/jats:title><jats:p>Although inflammation often decreases LDL cholesterol (LDL-C), and anti-inflammatory medications often increase LDL-C, both inflammation and anti-inflammatory medications can increase atherogenic Apolipoprotein B (ApoB)-containing lipoprotein particles, attenuated by statins. CVD risk factors, that is, smoking, obesity, ApoB, may increase years prior to IJD diagnosis. Increased risks of nonatherosclerotic myocardial and pulmonary disease, heart failure and mortality may be directly related to disease activity, inflammation, and possibly to HDL particles and function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>For IJD patients, higher cumulative lifetime exposure to CVD risk factors accelerates atherosclerosis and subsequent CVD risk that is underestimated by current risk factor levels. CVD risk reduction in IJD requires aggressive and earlier reduction in CVD risk factors (ApoB lipoproteins, smoking, hypertension, diabetes, lack of physical activity), in addition to control of disease activity and inflammation. Lipid-lowering medications can attenuate anti-inflammatory medication-induced increases in ApoB and LDL-C, but can also reduce CVD risk due to cumulative lifetime exposure.<\/jats:p><\/jats:sec>","DOI":"10.1097\/mol.0000000000000620","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T04:34:18Z","timestamp":1559190858000},"page":"342-349","source":"Crossref","is-referenced-by-count":4,"title":["Inflammatory joint diseases and atherosclerosis: time to look beyond the \u2018lipid paradox\u2019"],"prefix":"10.1097","volume":"30","author":[{"given":"Rachel H.","family":"Mackey","sequence":"first","affiliation":[{"name":"Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis H.","family":"Kuller","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry W.","family":"Moreland","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/art.39198","article-title":"Rheumatoid arthritis, anti-cyclic citrullinated peptide positivity, and cardiovascular disease risk in the women's health initiative","volume":"67","author":"Mackey","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.rdc.2018.03.006","article-title":"Update on cardiovascular disease risk in patients with rheumatic diseases","volume":"44","author":"Mackey","year":"2018","journal-title":"Rheum Dis Clin North Am"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/BOR.0000000000000378","article-title":"Lipids and lipid changes with synthetic and biologic disease-modifying antirheumatic drug therapy in rheumatoid arthritis: implications for cardiovascular risk","volume":"29","author":"Myasoedova","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"R5-20230917","doi-asserted-by":"crossref","DOI":"10.1002\/art.40889","article-title":"Exploring the lipid paradox theory in rheumatoid arthritis: associations of low circulating low density lipoprotein concentration with subclinical coronary atherosclerosis","author":"Giles","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/joim.12862","article-title":"Anti-inflammatory therapy for atherosclerosis: interpreting divergent results from the CANTOS and CIRT clinical trials","volume":"285","author":"Ridker","year":"2019","journal-title":"J Intern Med"},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jacc.2012.03.060","article-title":"High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis)","volume":"60","author":"Mackey","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"e002295","DOI":"10.1161\/JAHA.115.002295","article-title":"High-density lipoprotein subclasses and noncardiovascular, noncancer chronic inflammatory-related events versus cardiovascular events: the multi-ethnic study of atherosclerosis","volume":"4","author":"Duprez","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"e005549","DOI":"10.1161\/JAHA.117.005549","article-title":"Atherogenic lipoprotein determinants of cardiovascular disease and residual risk among individuals with low low-density lipoprotein cholesterol","volume":"6","author":"Lawler","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MED.0000000000000389","article-title":"Discordance between lipoprotein particle number and cholesterol content: an update","volume":"25","author":"Cantey","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2337\/dc14-0645","article-title":"Lipoprotein particles and incident type 2 diabetes in the multiethnic study of atherosclerosis","volume":"38","author":"Mackey","year":"2015","journal-title":"Diabetes Care"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jacl.2018.01.002","article-title":"Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: a post hoc analysis of the AIM-HIGH trial","volume":"12","author":"Otvos","year":"2018","journal-title":"J Clin Lipidol"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2018.11.001","article-title":"ApoB in clinical care: Pro and Con","volume":"282","author":"Sniderman","year":"2019","journal-title":"Atherosclerosis"},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","article-title":"Impact of lipids on cardiovascular health: JACC health promotion series","volume":"72","author":"Ference","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1373\/clinchem.2016.264515","article-title":"Discordance between circulating atherogenic cholesterol mass and lipoprotein particle concentration in relation to future coronary events in women","volume":"63","author":"Lawler","year":"2017","journal-title":"Clin Chem"},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering lipoprotein lipase (LPL) variants and LDL-C-lowering LDL receptor (LDLR) variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jama.2017.11467","article-title":"Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk","volume":"318","author":"Ference","year":"2017","journal-title":"JAMA"},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"e007402","DOI":"10.1161\/JAHA.117.007402","article-title":"Residual risk of atherosclerotic cardiovascular events in relation to reductions in very-low-density lipoproteins","volume":"6","author":"Lawler","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2018.10.059","article-title":"High-density lipoprotein particle subfractions in heart failure with preserved or reduced ejection fraction","volume":"73","author":"Hunter","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.atherosclerosis.2016.01.012","article-title":"High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort","volume":"246","author":"McGarrah","year":"2016","journal-title":"Atherosclerosis"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ahj.2018.04.003","article-title":"GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: the intermountain heart collaborative study","volume":"202","author":"Muhlestein","year":"2018","journal-title":"Am Heart J"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1373\/clinchem.2016.261636","article-title":"A novel protein glycan-derived inflammation biomarker independently predicts cardiovascular disease and modifies the association of HDL subclasses with mortality","volume":"63","author":"McGarrah","year":"2017","journal-title":"Clin Chem"},{"key":"R23-20230917","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12967-017-1321-6","article-title":"GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk","volume":"15","author":"Connelly","year":"2017","journal-title":"J Transl Med"},{"key":"R24-20230917","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1373\/clinchem.2016.255828","article-title":"Comparison of the predictive value of GlycA and other biomarkers of inflammation for total death, incident cardiovascular events, noncardiovascular and noncancer inflammatory-related events, and total cancer events","volume":"62","author":"Duprez","year":"2016","journal-title":"Clin Chem"},{"key":"R25-20230917","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13075-015-0646-x","article-title":"Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis","volume":"17","author":"Ormseth","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R26-20230917","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1177\/0961203315617842","article-title":"GlycA, a novel marker of inflammation, is elevated in systemic lupus erythematosus","volume":"25","author":"Chung","year":"2016","journal-title":"Lupus"},{"key":"R27-20230917","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3899\/jrheum.150437","article-title":"Longitudinal evaluation of lipoprotein variables in systemic lupus erythematosus reveals adverse changes with disease activity and prednisone and more favorable profiles with hydroxychloroquine therapy","volume":"43","author":"Durcan","year":"2016","journal-title":"J Rheumatol"},{"key":"R28-20230917","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1161\/CIRCRESAHA.116.309637","article-title":"GlycA is a novel biomarker of inflammation and subclinical cardiovascular disease in psoriasis","volume":"119","author":"Joshi","year":"2016","journal-title":"Circ Res"},{"key":"R29-20230917","doi-asserted-by":"crossref","DOI":"10.1002\/art.40904","article-title":"Rheumatoid arthritis disease activity predicting incident clinically-apparent RA-associated interstitial lung disease: a prospective cohort study","author":"Sparks","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R30-20230917","article-title":"Cardiovascular magnetic resonance characterization of myocardial and vascular function in rheumatoid arthritis patients","author":"Ntusi","year":"2018","journal-title":"Hellenic J Cardiol"},{"key":"R31-20230917","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ijcard.2018.06.099","article-title":"Anti-TNF modulation reduces myocardial inflammation and improves cardiovascular function in systemic rheumatic diseases","volume":"270","author":"Ntusi","year":"2018","journal-title":"Int J Cardiol"},{"key":"R32-20230917","article-title":"The effect of inflammation and infection on lipids and lipoproteins","author":"Feingold","year":"2018","journal-title":"Endotext"},{"key":"R33-20230917","doi-asserted-by":"crossref","first-page":"5L","DOI":"10.1016\/S0002-9149(00)01461-2","article-title":"The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review","volume":"86","author":"Kwiterovich","year":"2000","journal-title":"Am J Cardiol"},{"key":"R34-20230917","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s12026-016-8892-9","article-title":"Dyslipidemia in systemic lupus erythematosus","volume":"65","author":"Szabo","year":"2017","journal-title":"Immunol Res"},{"key":"R35-20230917","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.numecd.2018.06.022","article-title":"Small dense LDL cholesterol in human subjects with different chronic inflammatory diseases","volume":"28","author":"Schulte","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R36-20230917","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1373\/clinchem.2008.118356","article-title":"Apolipoprotein B and cardiovascular disease risk: position statement from the AACC lipoproteins and vascular diseases division working group on best practices","volume":"55","author":"Contois","year":"2009","journal-title":"Clin Chem"},{"key":"R37-20230917","doi-asserted-by":"crossref","first-page":"R116","DOI":"10.1186\/ar3842","article-title":"High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study","volume":"14","author":"Arts","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"R38-20230917","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3109\/03009742.2012.654815","article-title":"Apolipoprotein-defined lipoprotein abnormalities in rheumatoid arthritis patients and their potential impact on cardiovascular disease","volume":"41","author":"Knowlton","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"R39-20230917","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/rheumatology\/ker204","article-title":"Longitudinal levels of apolipoproteins and antibodies against phosphorylcholine are independently associated with carotid artery atherosclerosis 5 years after rheumatoid arthritis onset \u2013 a prospective cohort study","volume":"50","author":"Ajeganova","year":"2011","journal-title":"Rheumatology"},{"key":"R40-20230917","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.38920","article-title":"An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy","volume":"67","author":"Rao","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R41-20230917","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00296-015-3393-z","article-title":"Lipid profile among girls with systemic lupus erythematosus","volume":"37","author":"Machado","year":"2017","journal-title":"Rheumatol Int"},{"key":"R42-20230917","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12944-016-0229-0","article-title":"High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus","volume":"15","author":"Gaal","year":"2016","journal-title":"Lipids Health Dis"},{"key":"R43-20230917","doi-asserted-by":"crossref","first-page":"369","DOI":"10.5114\/aoms.2018.74021","article-title":"Serum lipid metabolism in psoriasis and psoriatic arthritis \u2013 an update","volume":"15","author":"Pietrzak","year":"2019","journal-title":"Arch Med Sci"},{"key":"R44-20230917","doi-asserted-by":"crossref","first-page":"e12873","DOI":"10.1111\/eci.12873","article-title":"Evidence for increased chylomicron remnants in rheumatoid arthritis","volume":"48","author":"Burggraaf","year":"2018","journal-title":"Eur J Clin Invest"},{"key":"R45-20230917","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/1756-185X.13159","article-title":"Favorable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"21","author":"Babary","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"R46-20230917","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/RHU.0000000000000502","article-title":"Use of hydroxychloroquine is associated with improved lipid profile in rheumatoid arthritis patients","volume":"23","author":"Restrepo","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"R47-20230917","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/annrheumdis-2017-211836","article-title":"Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"77","author":"Rempenault","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R48-20230917","doi-asserted-by":"crossref","first-page":"e13095","DOI":"10.1111\/ijcp.13095","article-title":"Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: a nationwide population-based cohort study","volume":"72","author":"Hung","year":"2018","journal-title":"Int J Clin Pract"},{"key":"R49-20230917","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11926-018-0752-2","article-title":"Cardiovascular safety of biologics and JAK inhibitors in patients with rheumatoid arthritis","volume":"20","author":"Kang","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"R50-20230917","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/art.39502","article-title":"Association of triple therapy with improvement in cholesterol profiles over two-year followup in the treatment of early aggressive rheumatoid arthritis trial","volume":"68","author":"Charles-Schoeman","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R51-20230917","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40264-017-0628-9","article-title":"The impact of biologics and tofacitinib on cardiovascular risk factors and outcomes in patients with rheumatic disease: a systematic literature review","volume":"41","author":"Nurmohamed","year":"2018","journal-title":"Drug Saf"},{"key":"R52-20230917","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.vph.2016.01.006","article-title":"Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis","volume":"81","author":"Naerr","year":"2016","journal-title":"Vascul Pharmacol"},{"key":"R53-20230917","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1136\/annrheumdis-2017-211708","article-title":"Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis","volume":"76","author":"Robertson","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R54-20230917","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/art.40036","article-title":"Effects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase IIb study of patients with active rheumatoid arthritis","volume":"69","author":"Kremer","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R55-20230917","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R56-20230917","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2018.07.001","article-title":"Effects of treatment with adalimumab on blood lipid levels and atherosclerosis in patients with rheumatoid arthritis","volume":"89","author":"Bergstrom","year":"2018","journal-title":"Curr Ther Res Clin Exp"},{"key":"R57-20230917","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/annrheumdis-2012-202089","article-title":"Effects of golimumab, an antitumour necrosis factor-alpha human monoclonal antibody, on lipids and markers of inflammation","volume":"73","author":"Kirkham","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R58-20230917","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.38974","article-title":"Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib","volume":"67","author":"Charles-Schoeman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R59-20230917","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2017-212461","article-title":"Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies","volume":"77","author":"Taylor","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R60-20230917","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacl.2017.06.012","article-title":"Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis","volume":"11","author":"Wolk","year":"2017","journal-title":"J Clin Lipidol"},{"key":"R61-20230917","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fmed.2018.00024","article-title":"The role of statins in disease modification and cardiovascular risk in rheumatoid arthritis","volume":"5","author":"Soulaidopoulos","year":"2018","journal-title":"Front Med"},{"key":"R62-20230917","first-page":"99","article-title":"Statins for prevention of cardiovascular disease in systemic lupus erythematosus","volume":"75","author":"Yousef Yengej","year":"2017","journal-title":"Neth J Med"},{"key":"R63-20230917","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/imm.12902","article-title":"Immune modulatory effects of statins","volume":"154","author":"Zeiser","year":"2018","journal-title":"Immunology"},{"key":"R64-20230917","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40744-016-0049-8","article-title":"Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis: a post hoc analysis","volume":"4","author":"Soubrier","year":"2017","journal-title":"Rheumatol Ther"},{"key":"R65-20230917","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","article-title":"Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R66-20230917","doi-asserted-by":"crossref","first-page":"e003822","DOI":"10.1161\/JAHA.116.003822","article-title":"Circulating N-linked glycoprotein side-chain biomarker, rosuvastatin therapy, and incident cardiovascular disease: an analysis from the JUPITER trial","volume":"5","author":"Akinkuolie","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"R67-20230917","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.3899\/jrheum.091175","article-title":"Nuclear magnetic resonance lipoprotein subclasses and the APOE genotype influence carotid atherosclerosis in patients with systemic lupus erythematosus","volume":"37","author":"Gonzalez","year":"2010","journal-title":"J Rheumatol"},{"key":"R68-20230917","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/rheumatology\/ker307","article-title":"Systemic lupus erythematosus risk factors for coronary artery calcifications","volume":"51","author":"Romero-Diaz","year":"2012","journal-title":"Rheumatology"},{"key":"R69-20230917","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/acr.21646","article-title":"Apolipoprotein B-containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis","volume":"64","author":"Knowlton","year":"2012","journal-title":"Arthritis Care Res"},{"key":"R70-20230917","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/1756-185X.12384","article-title":"Apolipoprotein B as an independent predictor of arterial stiffness in systemic lupus erythematosus patients","volume":"18","author":"Kwankaew","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"R71-20230917","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/acr.23594","article-title":"Patients with systemic lupus erythematosus show an increased arterial stiffness that is predicted by IgM antibeta2-glycoprotein I and small dense high-density lipoprotein particles","volume":"71","author":"Parra","year":"2019","journal-title":"Arthritis Care Res"},{"key":"R72-20230917","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.atherosclerosis.2012.08.029","article-title":"Complement system and small HDL particles are associated with subclinical atherosclerosis in SLE patients","volume":"225","author":"Parra","year":"2012","journal-title":"Atherosclerosis"},{"key":"R73-20230917","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2006.05.007","article-title":"LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the multi-ethnic study of atherosclerosis (MESA)","volume":"192","author":"Mora","year":"2007","journal-title":"Atherosclerosis"},{"key":"R74-20230917","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.bbacli.2015.03.005","article-title":"Lipoprotein particles and size, total and high molecular weight adiponectin, and leptin in relation to incident coronary heart disease among severely obese postmenopausal women: The Women's Health Initiative Observational Study","volume":"3","author":"Mackey","year":"2015","journal-title":"BBA Clin"},{"key":"R75-20230917","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10654-018-0360-5","article-title":"Smoking and susceptibility to rheumatoid arthritis in a Swedish population-based case\u2013control study","volume":"33","author":"Hedstrom","year":"2018","journal-title":"Eur J Epidemiol"},{"key":"R76-20230917","doi-asserted-by":"crossref","DOI":"10.1002\/acr.23837","article-title":"Impact and timing of smoking cessation on reducing risk for rheumatoid arthritis among women in the Nurses\u2019 Health Studies","author":"Liu","year":"2019","journal-title":"Arthritis Care Res"},{"key":"R77-20230917","doi-asserted-by":"crossref","DOI":"10.1002\/art.40852","article-title":"Smoking, HLA-genes and serology in rheumatoid arthritis; complex relationships investigated in the Swedish EIRA case\u2013control study","author":"Hedstrom","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R78-20230917","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13075-015-0560-2","article-title":"Physical activity and risk of rheumatoid arthritis in women: a population-based prospective study","volume":"17","author":"Di Giuseppe","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R79-20230917","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.semarthrit.2016.09.001","article-title":"Elevated BMI and antibodies to citrullinated proteins interact to increase rheumatoid arthritis risk and shorten time to diagnosis: a nested case\u2013control study of women in the Nurses\u2019 Health Studies","volume":"46","author":"Tedeschi","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"R80-20230917","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3945\/ajcn.114.086918","article-title":"Sugar-sweetened soda consumption and risk of developing rheumatoid arthritis in women","volume":"100","author":"Hu","year":"2014","journal-title":"Am J Clin Nutr"},{"key":"R81-20230917","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1136\/annrheumdis-2013-203338","article-title":"Long-term intake of dietary long-chain n-3 polyunsaturated fatty acids and risk of rheumatoid arthritis: a prospective cohort study of women","volume":"73","author":"Di Giuseppe","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R82-20230917","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1093\/rheumatology\/kex360","article-title":"The association between omega-3 fatty acid biomarkers and inflammatory arthritis in an anticitrullinated protein antibody positive population","volume":"56","author":"Gan","year":"2017","journal-title":"Rheumatology"},{"key":"R83-20230917","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12891-018-2381-3","article-title":"Association of fish intake and smoking with risk of rheumatoid arthritis and age of onset: a prospective cohort study","volume":"20","author":"Sparks","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"key":"R84-20230917","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/ard.2006.051672","article-title":"Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis","volume":"66","author":"van Halm","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R85-20230917","doi-asserted-by":"crossref","first-page":"e0193297","DOI":"10.1371\/journal.pone.0193297","article-title":"Pattern of risks of rheumatoid arthritis among patients using statins: a cohort study with the clinical practice research datalink","volume":"13","author":"de Jong","year":"2018","journal-title":"PLoS One"},{"key":"R86-20230917","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13075-017-1351-8","article-title":"Cardiovascular risk factors predate the onset of symptoms of rheumatoid arthritis: a nested case\u2013control study","volume":"19","author":"Kokkonen","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"R87-20230917","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/ard.2009.122374","article-title":"Total cholesterol and LDL levels decrease before rheumatoid arthritis","volume":"69","author":"Myasoedova","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R88-20230917","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1002\/art.27638","article-title":"The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner","volume":"62","author":"Deane","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R89-20230917","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.autrev.2018.02.007","article-title":"Impact of obesity on autoimmune arthritis and its cardiovascular complications","volume":"17","author":"Van Raemdonck","year":"2018","journal-title":"Autoimmun Rev"},{"key":"R90-20230917","doi-asserted-by":"crossref","first-page":"e006545","DOI":"10.1161\/JAHA.117.006545","article-title":"Association between smoking and serum glyca and high-sensitivity C-reactive protein levels: the multi-ethnic study of atherosclerosis (MESA) and Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)","volume":"6","author":"Kianoush","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"R91-20230917","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1136\/annrheumdis-2018-213444","article-title":"Apolipoprotein B binds to enolase-1 and aggravates inflammation in rheumatoid arthritis","volume":"77","author":"Lee","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R92-20230917","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.immuni.2016.11.008","article-title":"Cholesterol accumulation in CD11c(+) immune cells is a causal and targetable factor in autoimmune disease","volume":"45","author":"Ito","year":"2016","journal-title":"Immunity"},{"key":"R93-20230917","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1161\/ATVBAHA.118.310802","article-title":"Acute loss of apolipoprotein E triggers an autoimmune response that accelerates atherosclerosis","volume":"38","author":"Centa","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R94-20230917","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1373\/clinchem.2018.299636","article-title":"Low HDL cholesterol and high risk of autoimmune disease: two population-based cohort studies including 117341 individuals","volume":"65","author":"Madsen","year":"2019","journal-title":"Clin Chem"},{"key":"R95-20230917","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2796.2009.02123.x","article-title":"Prevalence and extent of calcification over aorta, coronary and carotid arteries in patients with rheumatoid arthritis","volume":"266","author":"Wang","year":"2009","journal-title":"J Intern Med"},{"key":"R96-20230917","doi-asserted-by":"crossref","DOI":"10.1177\/0961203317751060","article-title":"Associations of osteoprotegerin with coronary artery calcification among women with systemic lupus erythematosus and healthy controls","author":"Poornima","year":"2018","journal-title":"Lupus"},{"key":"R97-20230917","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/0961203319826689","article-title":"Incidence and predictors of aorta calcification in patients with systemic lupus erythematosus","volume":"28","author":"Hu","year":"2019","journal-title":"Lupus"},{"key":"R98-20230917","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/acr.23269","article-title":"Smoking behavior changes in the early rheumatoid arthritis period and risk of mortality during thirty-six years of prospective followup","volume":"70","author":"Sparks","year":"2018","journal-title":"Arthritis Care Res"},{"key":"R99-20230917","article-title":"Current and early life weight and associations with mortality in rheumatoid arthritis","author":"Baker","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"R100-20230917","first-page":"817","article-title":"Greater coronary heart disease risk with lower intensity and longer duration smoking compared with higher intensity and shorter duration smoking: congruent results across diverse cohorts","volume":"19","author":"Lubin","year":"2017","journal-title":"Nicotine Tob Res"},{"key":"R101-20230917","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/rheumatology\/kex038","article-title":"Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries","volume":"56","author":"Crowson","year":"2017","journal-title":"Rheumatology"},{"key":"R102-20230917","doi-asserted-by":"crossref","first-page":"e0174656","DOI":"10.1371\/journal.pone.0174656","article-title":"Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis","volume":"12","author":"Crowson","year":"2017","journal-title":"PLoS One"},{"key":"R103-20230917","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/art.38944","article-title":"The ability of the 2013 American College of Cardiology\/American Heart Association cardiovascular risk score to identify rheumatoid arthritis patients with high coronary artery calcification scores","volume":"67","author":"Kawai","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R104-20230917","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3899\/jrheum.170025","article-title":"Underestimation of risk of carotid subclinical atherosclerosis by cardiovascular risk scores in patients with psoriatic arthritis","volume":"45","author":"Shen","year":"2018","journal-title":"J Rheumatol"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00041433-201908000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T21:16:17Z","timestamp":1721337377000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041433-201908000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":104,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000620","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}